Pharmaceutical Market Europe • October 2022 • 38-40
APPOINTMENTS
Novartis
Fiona Marshall
Novartis has appointed Fiona Marshall as president of the Novartis Institutes for BioMedical Research. Prior to joining Merck in 2018, Marshall was a founder and chief scientific officer of Heptares Therapeutics and, earlier in her career, she served as director of molecular pharmacology at Millennium Pharmaceuticals. She also spent ten years at GSK, holding senior positions in molecular pharmacology and Neuroscience. Marshall is the recipient of the 2012 WISE Women of Outstanding Achievement for Innovation and Entrepreneurship Award, the 2015 RSC Malcolm Campbell Award for chemistry and the Vane Medal from the British Pharmacological Society. She is also a Fellow of the Royal Society and the Academy of Medical Sciences, and is Honorary Fellow of the British Pharmacological Society.
Vico Therapeutics
Micah Mackison
Vico Therapeutics has appointed Micah Mackison as its chief executive officer. Mackison brings significant biotechnology and pharmaceutical experience, having served at Locanabio as its chief business officer and executive vice president of strategy and corporate development. He was senior vice president, corporate development and strategy at Assembly Biosciences. He also held finance roles at Eli Lilly and Pfizer.
STORM Therapeutics
Jerry McMahon
STORM Therapeutics has appointed of Jerry McMahon as president and chief executive officer and board director. McMahon brings over 30 years’ biotechnology leadership with a specialty in oncology. He served as president and chief executive officer at Harpoon Therapeutics from 2016 to 2021, and served at Yale University as its adjunct professor medical oncology and Yale Comprehensive Cancer Center.
Bright Peak Therapeutics
Jon Wigginton
Bright Peak Therapeutics has appointed Jon Wigginton as president of research and development.
Wigginton is an expert in immunotherapy drug development with over 25 years’ experience in clinical oncology. He served as senior advisor and chairman of the Scientific Advisory Board at Cullinan Oncology, having served as the company’s chief medical officer.
MorphoSys
Tim Demuth
MorphoSys has appointed Tim Demuth as chief of research and development officer. With 20 years’ experience, Demuth served as chief medical officer of Pieris and was vice president and head of global clinical development oncology at Merck KGaA. He also led the Clinical Development Unit of Hematology Biopharma Development at Sandoz AG. Demuth held roles at Novartis, Italfarmaco and Merck & Co.
Macomics
Thomas Crozier
Macomics has appointed Thomas Crozier as a senior scientist. Crozier joins from the University of Cambridge and brings over ten years of research experience. He offers extensive knowledge into the use of unbiased genome and proteome-wide approaches to gene and protein function in a range of biological systems. Crozier received his PhD from the University of Dundee.
Macomics
Yuxin Cui
Macomics has appointed Yuxin Cui as a senior bioinformatician. Cui specialises in the bioinformatic analysis of large-scale multi-omics data and has served at Apitope as a senior research scientist in clinical immunology. He has been a research fellow at Cardiff University and he obtained his PhD from the University of Nottingham School of Pharmacy.
Oxford Drug Design
Richard Cooper
Oxford Drug Design has appointed Richard Cooper as its head of machine learning. Cooper is a computational chemist and previously served as head of chemical crystallography at the University of Oxford. There, his research has focused on method development for crystal structure modelling tools and combining chemical descriptors, as well as machine learning.
SpectrumX
Heather Lloyd
SpectrumX has appointed Heather Lloyd as a microbiologist. Lloyd has an extensive background in evaluating antimicrobial efficacy of both industrial and cosmetic product samples, with an interest in antimicrobial resistance research. She most recently served as a microbiologist at Thor Specialities where she began her career working as a microbiology lab technician.
Merck
George Addona
Merck has appointed George Addona as senior vice president and head of discovery, preclinical and translational medicine at Merck Research Laboratories. Addona joined Merck in 2008 and has served as vice president, quantitative biosciences and as associate vice president, pharmacology.
Prior to leading QB, he directed teams in Boston, South San Francisco and Singapore and has offered vital leadership in progressing multiple ongoing development programmes covering cardio-metabolic, infectious disease, neuroscience and oncology indications. He previously served at Novartis as a group leader, Novartis Institutes for Biomedical Research, and in 2000, he served as a senior scientist at Praecis Pharmaceuticals. Addona holds a BA in Biochemistry from Rutgers College, a PhD in Chemistry from the University of Virginia and conducted postdoctoral research at Harvard’s Department of Biological Chemistry and Molecular Pharmacology.
Celsius Therapeutics
Sarah Grant
Celsius Therapeutics has appointed Sarah Grant as chief medical officer. Grant brings over 20 years’ experience in translational medicine, drug development and clinical medicine. She spent nine years at Novartis in multiple senior leadership roles, most recently as the chief of staff and strategic assistant for the head of global drug development. She was also head of respiratory discovery within translational medicine.
SOTIO Biotech
Martin Steegmaier
SOTIO Biotech has appointed Martin Steegmaier as chief scientific officer. Steegmaier brings over 20 years’ experience, having previously served as the global head of research at MorphoSys following its acquisition of Constellation Pharmaceuticals. He was group leader at Boehringer Ingelheim’s Oncology Drug Discovery Department and joined Roche Pharmaceuticals as head of discovery for molecule research.
SpectrumX
Annaliese Waite
SpectrumX has appointed Annaliese Waite as its head of microbiology. Waite brings a wealth of microbiology experience, having worked at AstraZeneca on the development of rapid sterility testing for the COVID-19 vaccine. She was a member of the technical team at antimicrobial technologies company, Byotrol, where she worked on microbiological testing and conducting preparatory procedures for quality control.
Tessera Therapeutics
Anne-Virginie Eggimann
Tessera Therapeutics has appointed Anne-Virginie Eggimann as its chief regulatory officer. Eggimann most recently served at bluebird bio for nearly 11 years and has gained more than 20 years of knowledge and experience in the development of innovative medicinal products. She previously served as executive director at Voisin Consulting Life Sciences and currently serves on the board of Codiak Biosciences.
Tessera Therapeutics
Derica Rice
Tessera Therapeutics has appointed Derica Rice to its board of directors. Rice has a background in managing financial matters, having led the pharmacy benefits business of CVS Health as operational, executive vice president and president of CVS Caremark. He spent 27 years working at Eli Lilly, eventually serving as executive vice president of global services and as chief finance officer.
Genomics
Simon Dingemans
Genomics has appointed Simon Dingemans as its new chair of the board. Dingemans offers a background spanning 25 years, having served as group chief financial officer of GSK. He is currently a senior advisor to The Carlyle Group and is also on the board of WPP as a non-executive director, and served for four years as a Trustee and Chair of the Audit Committee of London.
Macomics
Valérie Méresse Naegelen
Macomics has appointed Valérie Méresse Naegelen to its panel of clinical advisors. She brings over 20 years’ experience in oncology research and clinical development to the role. She started her career at Roche in 2001, serving for over 20 years, and currently as global head of translational science technology oversees Roche’s translational activities. She served as translational medicine leader for pRED oncology.
Oxford Drug Design
Xiang-Lei Yang
Oxford Drug Design has appointed Xiang-Lei Yang to its Scientific Advisory Board. Yang is the Ernest W Hahn Endowed chair and Professor of molecular medicine at The Scripps Research Institute. She is co-principal investigator of the Scripps Laboratory for tRNA Synthetase Research. She received her BS in Biomedical Engineering at Capital Institute of Medical Science, Beijing.
OPEN Health
Stephen Chick
OPEN Health has appointed Stephen Chick as chief growth officer for OPEN Health Evidence & Access. Chick offers extensive experience having served as vice president of business development for Symphony Health, and worked as a managing principle at Consumer Healthcare Insights Consulting. He was vice president and general manager of life sciences at Allscripts.
Envision Pharma Group
Meg Heim
Envision Pharma Group has appointed Meg Heim as its new chief executive officer. With a strong comms background, Heim has previously served at Healios as a director on its board of directors and is also a member of the Women Business Leaders of the US Health Care Industry Foundation (WBL). She is also president and founder of Heim Global Consulting, specialising in scientific strategy.
Havas Health & You
Laura Mizrahi
Havas Health & You has appointed innovative creative leader Laura Mizrahi as chief creative officer (CCO) of H4B Chelsea. With over 20 years of extensive experience, she has worked with Cialis, Trulicity and Skyrizi. She previously served at FCB Health NY as executive vice president and executive creative director. She also served as senior vice president and executive creative director at Razorfish Health.
Uptake Strategies
Maxine Smith
Uptake Strategies has appointed Maxine Smith as managing director. Smith has over 20 years' experience in the pharmaceutical and healthcare industries. She previously served at Blue Key Marketing as a healthcare consultant and managing director and also served at Sanofi in various senior roles. In 2001, she served as senior global product strategy manager at GSK.
The Creative Engagement Group
Tom Griffiths
The Creative Engagement Group has appointed Tom Griffiths as its strategy and planning director
Griffiths joins the Group from Saatchi & Saatchi Wellness where he was an integrated strategy director and prior to that, served as digital strategy director in the greyhealth group. He brings a wealth of healthcare comms experience, having driven brand strategy for Bayer, Pfizer, Sanofi, Galderma and GSK.
Inizio Biotech
Jay Janus
Inizio Biotech has appointed Jay Janus as senior account director. Janus will work as a primary contact for emerging biotech partners He brings extensive biostatistics and medical writing experience to the role, having most recently served as director of client services at BioBridges. He served for four years at Supplemental Health Care in roles including market manager, regional manager and staffing manager.
Fishawack Health
Geoff Thorne
Fishawack Health has appointed Geoff Thorne as chief technology officer. Thorne offers a wealth of experience, having served at Digitas Health for over 16 years, in various roles, which included as lead technical executive, leading a team of over 70 technologists. Prior to this role, he worked as the company’s senior software engineer and in the early 2000s, Thorne served as a senior web developer.
Genesis Research
Jennifer Fillman
Genesis Research has appointed Jennifer Fillman as its new chief financial officer. Fillman offers 27 years of financial experience, alongside in-depth understanding of the pharmaceutical industry. Before joining Genesis, she served as senior vice president and chief financial officer, clinical solutions at Syneos Health. Prior to Syneos Health, she served in various roles at Cardinal Health, including as general manager of four pharma business units.
Beckman Coulter Life Sciences
Suzanne Foster
Beckman Coulter Life Sciences has appointed Suzanne Foster as president. With over 25 years’ experience in the healthcare industry, Foster joins from Cardinal Health, where she spent two years serving as president of the Health-at-Home business. She previously served as president of Healthcare at Stanley Black & Decker, and at Medtronic as general manager of its Advanced Energy business.
Brainomix
Jérôme Galbrun
Brainomix has appointed Jérôme Galbrun as chief revenue officer. Galbrun brings extensive experience, having served as senior director at Philips, where he was lead global business development for the Electronic Medical Records and Care Management Business Unit. He was the head of global business development at Agfa HealthCare and served at Hewlett-Packard and GE Healthcare.
Elevar Therapeutics
Gordon Schooley
Elevar Therapeutics has appointed Gordon Schooley as chief regulatory officer. Schooley has over 30 years’ experience, and joins Elevar from BeyondSpring Pharmaceuticals, where he served as chief regulatory officer. He spent seven years as a consultant for drug development activities. He also served at SkyePharma PLC/Pacira Pharma, Alliance Pharmaceuticals and Allergan/Herbert Labs.
Macomics
Lisa Seymour
Macomics has appointed Lisa Seymour as operations manager and health and safety officer. Seymour served at the Wellcome Trust Sanger Institute where she served for seven years as an advanced laboratory technician in clinical microbiology, virology and parasitology. She is a member of the Institution of Occupational Safety and Health and the Royal Society of Biology.